Lihong Fan1, Jie Sha2, Junliang Teng3, Dan Li4, Changhui Wang1, Qing Xia1, Hao Chen1, Bo Su5, Huiwei Qi6. 1. Department of Respiration Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 2. Department of Respiration Medicine, Shanghai Tenth People's Hospital, Nanjing Medical University, Nanjing, China. 3. School of Information Management and Engineering, Shanghai University of Finance and Economics, Shanghai, China. 4. Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 5. Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China. su_bo_s@hotmail.com. 6. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China. huiwei_queen@163.com.
Abstract
BACKGROUND AND OBJECTIVE: To clarify whether there are different expressions between lung cancer and benign pulmonary diseases, we studied seven microRNAs (miRNAs) in serum from patients with non-small cell lung cancer (NSCLC), benign pulmonary nodules and four pulmonary inflammation diseases. METHODS: We detected the expression of miRNAs using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). RESULTS: We found that five miRNA ratios-miR-15b-5p/miR-146b-3p, miR-20a-5p/miR-146b-3p, miR-19a-3p/miR-146b-3p, miR-92a-3p/miR-146b-3p, and miR-16-5p/miR-146b-3p-show higher expression in the NSCLC group than the benign pulmonary nodule group, and 13 ratios of miRNAs were significantly upregulated in the NSCLC group compared with the pulmonary inflammation diseases group. Receiver operating characteristic (ROC) curve analysis was performed. For NSCLC and benign pulmonary nodules, the sensitivity and specificity were 0.70 and 0.90, respectively. For NSCLC and pulmonary inflammation diseases, the sensitivity and specificity were 0.81 and 0.71, respectively. CONCLUSION: The ratios of miRNAs can be used as potential non-invasive biomarkers for diagnosis of early-stage NSCLC and benign pulmonary diseases.
BACKGROUND AND OBJECTIVE: To clarify whether there are different expressions between lung cancer and benign pulmonary diseases, we studied seven microRNAs (miRNAs) in serum from patients with non-small cell lung cancer (NSCLC), benign pulmonary nodules and four pulmonary inflammation diseases. METHODS: We detected the expression of miRNAs using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). RESULTS: We found that five miRNA ratios-miR-15b-5p/miR-146b-3p, miR-20a-5p/miR-146b-3p, miR-19a-3p/miR-146b-3p, miR-92a-3p/miR-146b-3p, and miR-16-5p/miR-146b-3p-show higher expression in the NSCLC group than the benign pulmonary nodule group, and 13 ratios of miRNAs were significantly upregulated in the NSCLC group compared with the pulmonary inflammation diseases group. Receiver operating characteristic (ROC) curve analysis was performed. For NSCLC and benign pulmonary nodules, the sensitivity and specificity were 0.70 and 0.90, respectively. For NSCLC and pulmonary inflammation diseases, the sensitivity and specificity were 0.81 and 0.71, respectively. CONCLUSION: The ratios of miRNAs can be used as potential non-invasive biomarkers for diagnosis of early-stage NSCLC and benign pulmonary diseases.
Authors: Magdalena B Wozniak; Ghislaine Scelo; David C Muller; Anush Mukeria; David Zaridze; Paul Brennan Journal: PLoS One Date: 2015-05-12 Impact factor: 3.240
Authors: Qiang Li; Yao Liu; Jiajia Bai; Song Zhao; Yawen Wang; Arzoo Shabbir; Kai Zhang; Fan Jiang; Jiang Zhu; Rong Ma; Jianli Wang Journal: BMC Womens Health Date: 2022-02-05 Impact factor: 2.809